Extracted from this filing and checked against the source text.
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
Sana Biotechnology, Inc. entered into Underwriting Agreement with Morgan Stanley & Co. LLC, J.P. Morgan Securities LLC, Goldman Sachs & Co. LLC, and BofA Securities, Inc., as representatives valued at approximately $156.6 million (effective 2024-02-07).
- Action
- entry
- Agreement
- underwriting
- Counterparty
- Morgan Stanley & Co. LLC, J.P. Morgan Securities LLC, Goldman Sachs & Co. LLC, and BofA Securities, Inc., as representatives
- Value
- approximately $156.6 million
- Effective
- 2024-02-07
Exact text from the filing
On February 7, 2024, Sana Biotechnology, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Morgan Stanley & Co. LLC, J.P. Morgan Securities LLC, Goldman Sachs & Co. LLC, and BofA Securities, Inc., as representatives (the “Representatives”) of the several underwriters named therein (collectively, the “Underwriters”), relating to the issuance and sale in a public offering (the “Offering”) of 17,272,728 shares of the Company’s common stock, par value $0.0001 per share, at a price to the public of $5.50 per share (the “Underwritten Shares”), and pre-funded warrants (the “Pre-Funded Warrants”) to purchase 12,727,272 shares of the Company’s common stock at a price to the public of $5.4999 per underlying share.
View on SEC.gov